adverse events

In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Joleen Hubbard MD

Cathy Eng, MD

Stephanie Andrews, MS, APRN-C

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.

Email: Uncommonpodcast@outlook.com

Facebook: @UncommonPOD

Twitter: @UncommonPC 

Instagram:  @dustin.duff     @Bpop80    

Gettr: @Duffdb

Gab: @Duffdb  

Clips:

Fuck Your Feelings Song:

Battleplan Fauci

https://battleplan.news/watch?id=6226eae9ba680459ec8f3e62

Moderna CEO on genetic sequencing of vax and covid

https://noagendaassets.com/enc/1645997560.37_modernapresidentbancelgetscalledoutbymoneyhoneyforhavingthesamegeneticsequencepatented3yearsbeforethepandemic.mp3

Biden: Government Spending Doesn’t Lead to Inflation

https://noagendaassets.com/enc/1647202455.293_bidenissickofpeoplethinkinginflationisbecuaseofgovernmentsspendingmoremoney.mp3

Takes Naps “Woman of the Year” 

https://www.instagram.com/reel/CbLBliPgev1/?utm_medium=copy_link 

Biden Aid to Ukraine

https://noagendaassets.com/enc/1647202469.123_moreaidtoukrainenpr.mp3

Scott Ritter (Fmr USMC) Explains US finding of Nazis in 2014-2022

https://noagendaassets.com/enc/1647202499.205_scottritter-frmrusmc-explainsusfindingofnazisin2014-2022.mp3

Dr Ryan Cole Pfizer Doc Release

https://twitter.com/drsimonegold/status/1503840470799159306?s=20&t=_5TUk9wCVyO8cuS-k44jPA

Schwab Gene Editing

https://noagendaassets.com/enc/1647202484.817_klauschwab4thindustrialrevolutionchangesyouwithgeneediting-charlierose.mp3

Pfizer 4th Shot

https://noagendaassets.com/enc/1647548286.53_abcgma-anchorevapilgrim-phizer4thshotb.a.21min.mp3

Biden Funding Ukraine

https://noagendaassets.com/enc/1647548337.219_abcgma2anchorceciliavega-listofweaponsgiventoukraine1min13sec.mp3

Edward Dowd [Frmr Blackrock] DEMOCIDE - CDC data shows massive excess mortality in millennials AFTER JABS

https://noagendaassets.com/enc/1647202499.205_edwarddowdfrmrblackrockdemocide-cdcdatashowsmassiveexcessmortalityinmillennialsafterjabs.mp3 

Ukraine universal basic income only with digital COVID vax pass

https://twitter.com/IrishAmerican27/status/1504601539716993035?s=20&t=qnUEnLF2prVHNOS5SJSeIA

Connect with Brett on Facebook, Instagram, & X @BPOP80

Watch full length episodes on YouTube at https://www.youtube.com/@brettpopish

Be sure to rate this podcast on whatever platform you're listening on and remember #BeDEFIANT

In this episode, Jason Schafer, PharmD, MPH, explores recommendations and data on managing antiretroviral therapy (ART) in the inpatient setting.

Listen as he gives his perspectives on:

• Antiretroviral stewardship to prevent medication errors in the inpatient setting and at transitions of care
• Renal and hepatic dosing considerations for ART
• Drug–drug interaction considerations between ART and medications commonly encountered in the inpatient setting
• Antiretroviral food effects
• Administration of antiretrovirals in persons with swallowing difficulties

Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Follow along with the slides at:
https://bit.ly/36h5tOC

See the entire program at: 
https://bit.ly/3q2DlGd

In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

David Ilson, MD

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.

In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Amit Singal, MD, MS

Mark Yarchoan, MD

Bridget O’Brien, DNP, FNP-BC, AOCNP

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.

Action Items

Johns Hopkins Study Shows Lockdowns Didn't Work - https://sites.krieger.jhu.edu/iae/files/2022/01/A-Literature-Review-and-Meta-Analysis-of-the-Effects-of-Lockdowns-on-COVID-19-Mortality.pdf

1000 Studies Show Vaccine Adverse Effects - https://www.thegatewaypundit.com/2022/02/list-1000-different-studies-show-extensive-evidence-covid-19-vaccines-adverse-events/

CDC Study Shows Vaccines Wane After 4 Months - https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm?s_cid=mm7107e2_w

News Items

https://www.lewrockwell.com/2022/02/no_author/international-group-of-attorneys-proceed-with-covid-19-crimes-against-humanity-grand-jury/

https://www.thegatewaypundit.com/2022/02/done-wearing-masks-brave-students-across-washington-state-protest-masks-schools-video/

https://edmonton.ctvnews.ca/alberta-ditches-proof-of-vaccine-program-at-midnight-masking-for-students-monday-1.5772684

https://www.thegatewaypundit.com/2022/02/following-statewide-school-mask-mandate-suspension-illinois-teachers-begin-harassing-threatening-students-teachers-union-vows-maskless-children-will-dealt/

https://www.wnd.com/2022/02/state-ag-rules-doctors-can-prescribe-ivermectin-hydroxychloroquine/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=%5B-MD5-%5D

https://www.theepochtimes.com/video-parents-shoved-denied-access-to-pennsylvania-school-board-meeting_4270325.html?utm_source=News&utm_campaign=breaking-2022-02-11-1&utm_medium=email&est=G3Iofu8uDWVUKKGW07yAv31J7TC%2BRowWS59Bw4UIrgIqhuCpSNEcY6i7INs%3D

https://www.thegatewaypundit.com/2022/02/wow-last-week-experts-admitted-lockdowns-not-reduce-mortality-rates-now-admit-masking-mostly-worthless/

https://www.theatlantic.com/ideas/archive/2022/02/end-coronavirus-restrictions/621627/

https://www.bloomberg.com/opinion/articles/2022-02-11/did-mask-mandates-work-the-data-is-in-and-the-answer-is-no

https://www.zerohedge.com/markets/natural-immunity-and-other-conspiracy-theories-have-magically-become-fact-checked

https://www.zerohedge.com/covid-19/watch-johns-hopkins-prof-slams-media-own-institution-hiding-bombshell-study-found?utm_source=&utm_medium=email&utm_campaign=460

https://www.thegatewaypundit.com/2022/02/list-1000-different-studies-show-extensive-evidence-covid-19-vaccines-adverse-events/

https://www.wnd.com/2022/02/pentagon-flubs-response-recorded-spike-injuries-possibly-tied-vaccines/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=1c0954f1b62809b09a100d75c701d474

https://www.thegatewaypundit.com/2022/02/dod-caught-major-scandal-us-military-caught-severe-data-manipulation-following-covid-reveal-no-way-revised-numbers-real/

https://www.thegatewaypundit.com/2022/02/biden-administration-recalculate-number-covid-19-hospitalizations-determine-people-came-covid-covid/

https://www.wnd.com/2022/02/democrats-flip-flop-covid-midterms-approach/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=%5B-MD5-%5D

https://www.cbc.ca/news/politics/trudeau-premiers-cabinet-1.6350734

https://www.thegatewaypundit.com/2022/02/outrageous-ottawa-policemen-arrested-78-year-old-man-meant-no-harm-honking-video/

https://www.buzzfeednews.com/article/paulmcleod/canadian-truckers-ottawa-convoy-police-worldwide

https://www.thegatewaypundit.com/2022/02/hundreds-thousands-demonstrate-freedom-tyrannical-government-outside-parliament-house-canberra-australia-video/

https://apnews.com/article/coronavirus-pandemic-health-barry-manilow-new-zealand-riots-e837ee102dc43a1f5f224729c461ced6

https://www.thegatewaypundit.com/2022/02/insane-austrian-government-authorizes-dystopian-vaccine-registry-imposes-covid-restrictions-january-2024-will-begin-pulling-drivers-random-fining-un-boosted-citizens-next-mo/

https://www.thegatewaypundit.com/2022/02/know-dont-china-not-administered-single-mrna-vaccine-1-45-billion-citizens/

https://www.theepochtimes.com/japan-put-a-warning-label-on-covid-19-shots_4270030.html?utm_source=Health&utm_campaign=health-2022-02-11&utm_medium=email&est=3LbgiyHfq%2FNqHT3aRYLzVIVXriIr23T1hAgvjqt9QAFNb%2FYEmo7AxFEGAZY%3D

https://thehill.com/policy/international/594012-freedom-convoy-protests-in-paris-block-traffic-as-police-attempt-to?rl=1

https://pjmedia.com/news-and-politics/rick-moran/2022/02/11/french-president-macron-refused-to-take-russian-covid-test-fearing-russians-would-steal-his-dna-n1558398

https://www.infowars.com/posts/live-updates-police-forces-attack-arrest-freedom-convoy-protesters-around-the-world/

https://www.thegatewaypundit.com/2022/02/free-press-dead-covid-lockdowns-back-place-people-hong-kong-punished-free/

https://www.wnd.com/2022/02/embalmer-alarmed-mysterious-blood-clots-vaccinated-people/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=%5B-MD5-%5D

https://www.thegatewaypundit.com/2022/02/covid-booster-effectiveness-wanes-4-months-cdc-says/

https://report.drudgenow.com/article/?u=https://www.foxnews.com/politics/california-celebrities-flouting-mask-mandate-while-enjoying-super-bowl-lvi&n=0&s=2&c=1&pn=Anonymous

https://www.theepochtimes.com/world-economic-forum-endorses-critical-race-theory_4275110.html

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:

• Testing for targetable biomarkers
• Talking with patients about biomarker testing
• Frontline therapy for EGFR-positive NSCLC
• Resistance to front-line osimertinib
• Treatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecan
• HER3 protein testing
• Pathology considerations
• Nursing considerations
• Interdisciplinary communication

Presenters:

Conor Ernst Steuer, MD
Assistant Professor
Department of Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Frank Schneider, MD
Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Director, Cancer Tissue and Pathology Shared Resource
Winship Cancer Institute
Emory University
Atlanta, Georgia

Elise Hitron, MSN, FNP-C
Adjunct Instructor
School of Nursing
Phase I Clinical Trials Nurse Practitioner
Winship Cancer Institute
Emory University
Atlanta, Georgia

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:
https://bit.ly/3G32Jkm

Email: Uncommonpodcast@outlook.com

Twitter: @UncommonPC

Dustin Instagram: @dustin.duff

Brett Instagram: @Bpop

#UNCOMMONPODCAST #Uncensored #Defundpolitics #Defeundthemedia #Plandemic #TGR #Truth 

Clips:

Dr. who spotted Omicron says symptoms are mild:

https://rumble.com/vpxeua-omicron-symptoms-mild-says-doctor-who-spotted-it.html

Dr. John Campbell on Ivermectin in Japan:

https://www.dropbox.com/s/ntjsq4zvupdheea/Dr%20John%20Campbell%20on%20Ivermectin%20in%20japan.mp3?dl=0 

Dr. Aseem Malhorta GBNews UK - Vaccine adverse advents of the HEART:

 https://www.dropbox.com/s/jd8dtvmm78j51qj/Dr%20Aseem%20Malhorta%20GBNews%20UK%20-%20Vaccine%20adverse%20advents%20of%20the%20HEART.mp3?dl=0

Connect with Brett on Facebook, Instagram, & X @BPOP80

Watch full length episodes on YouTube at https://www.youtube.com/@brettpopish

Be sure to rate this podcast on whatever platform you're listening on and remember #BeDEFIANT

In this episode, Ayesha discusses the FDA’s authorization of Pfizer/BioNTech’s COVID-19 vaccine for children between five and 11 years of age. The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. Amid concerns of the rare adverse event of myocarditis in children and adolescents following vaccination with mRNA vaccines, the FDA conducted its own benefit-risk analysis that showed the benefit of vaccination outweighs the risk of myocarditis. The editorial team discussed the positive trial data, the importance of vaccinating kids amid rising infections among younger children, as well as vaccine hesitancy among parents.

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). The implant is surgically placed in the eye and injected with Genentech’s anti-VEGFA monoclonal antibody ranibizumab for continuous delivery. Compared with the current standard of care of near monthly intravitreal anti-VEGF injections, the ocular implant only has to be refilled every six months. The team discussed the convenience of the device, but also potential patient hesitancy over the surgery for its implantation.

Read the full articles here: 

FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11 

Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:

• At what time in the treatment journey should CAR T-cell therapy be considered?
• How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
• How is CAR T-cell therapy best used for multiple myeloma?
• What qualities of bridging therapy are most preferred?
• When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?  
• How are steroids optimally used in managing CAR T-cell therapy–related toxicities?

Presenters:

Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park, MD
Associate Member  
Leukemia Service and Cellular Therapeutics Center  
Memorial Sloan Kettering Cancer Center
New York, New York

Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center  
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/3BfbEOf

In this episode,  Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:

• Approaches for managing smoldering multiple myeloma
• Insights on new strategies for managing newly diagnosed multiple myeloma
• Incorporating newly approved agents in the frontline and early relapse setting
• Choosing and sequencing BCMA-targeted therapies
• Managing patients with refractory multiple myeloma

Presenters:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.

Link to full program, including downloadable slidesets and expert commentaries:
https://bit.ly/39MWNid

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

• Germline and somatic mutation testing
• Managing adverse events with PARP inhibitors
• Resistance to PARP inhibitors
• Implications of monoallelic vs biallelic BRCA mutations
• ATM mutations and PARP inhibitor sensitivity

Presenters:

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:

• Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?
• Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?
• What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?
• What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?

Presenter:

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.

Link to full program:
http://bit.ly/3rDeFCV 

What’s the likelihood that you as a healthcare professional can be emotionally triggered by your work? Trauma and adverse events within health care settings impact everyone. Studies indicate that many healthcare professionals suffer in silence as they deal with anxiety, stress, shame, and guilt as a result of adverse clinical and traumatic experiences / events. Instead of suffering in silence, physicians, medical students, and healthcare professionals need to have a safe space and resources to talk about the trauma they experience and receive the appropriate support they need and deserve.

Remember, even though you are a healthcare professional, you are also just as human and vulnerable as your patients...

-What unresolved emotions reside in you?
-What memories and experiences do you take home from the hospital or clinic?
-Who are you becoming as you practice in your field of expertise?
-How is your healthcare career affecting your life, your health, your relationships?

You can have a career in healthcare with resources that support you on both a personal and professional level.

Heart First Medicine Academy has just what you are looking for! The first FREE online masterclass "Rehab for the Heart" is being held in February.

Message Dr. Deb Howell for more information at https://www.facebook.com/drdebhowell/

Happy New Year and welcome to the first episode of 2020!  We've got some great articles to review today.  Can we save money by taking care of some acutely ill patients in their own homes?  Are patients admitted for "social" reasons at the same risk for adverse events as acutely ill patients?  Can NT-ProBNP level predict cardiovascular death and myocardial injury after non-cardiac surgery?  Does limiting alcohol intake reduce atrial fibrillation recurrence?  Listen to find out!

Hospital Level Care at Home for the Acutely Ill

Adverse Events in Patients Hospitalized Without Definite Medical Acuity

Preoperative NT-ProBNP before Non-Cardiac Surgery

Alcohol Abstinence and Atrial Fibrillation








Music from https://filmmusic.io
"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)
License: CC BY (http://creativecommons.org/licenses/by/4.0/)